RBC raises Fortive stock price target to $85 from $77

On Monday, RBC Capital Markets updated its outlook on Fortive Corporation (NYSE:FTV), a diversified industrial technology conglomerate with a market capitalization of $27.5 billion, by increasing the price target to $85.00, up from the previous $77.00. The firm has maintained a Sector Perform rating on the stock. According to InvestingPro data, the stock currently trades at a relatively high P/E ratio of 33.7, suggesting premium valuation levels.

The adjustment follows Fortive’s fourth-quarter earnings report for the year 2024, which showed a slight miss in operating income by $0.02 and a 2% deviation from RBC Capital’s and the consensus estimates. This was attributed to weaker than expected revenue and margins in Fortive’s Professional Instrumentation (PT) segment. Despite this, the company’s guidance for 2025 aligns with the high end of RBC Capital’s estimates. InvestingPro analysis reveals the company maintains impressive gross profit margins of nearly 60% and operates with a moderate debt level, earning a GOOD overall Financial Health Score.

A highlight for Fortive during the quarter was the strong orders momentum within its PT segment, marking a double-digit percentage increase for the second consecutive quarter. Additionally, the company demonstrated robust free cash flow (FCF) conversion at 114%, consistent with its average for the fourth quarter.

Looking ahead, Fortive anticipates that the market challenges in China will continue through the year 2025. However, there was a positive development regarding the timeline for the planned spin-off of the PT segment into a new company, Ralliant. Initially scheduled for the fourth quarter of 2025, the separation is now expected to occur earlier, in the third quarter of the year. This development is seen as a benefit as it reduces the period during which Fortive might face uncertainties related to the transaction.

In his commentary, the RBC Capital analyst noted the balanced risk/reward profile for Fortive shares. The earlier than anticipated spin-off of the PT segment is a key positive, potentially alleviating some concerns for investors regarding the company’s strategic direction and focus for the coming year. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with 8 additional ProTips and a detailed Pro Research Report, providing valuable context for evaluating Fortive’s strategic moves and financial outlook.

In other recent news, Fortive Corporation has been the subject of attention due to its recent financial performance and analysts’ projections. Raymond (NSE:RYMD) James maintained a positive outlook on the company, raising its stock target to $90, following Fortive’s impressive fourth-quarter results. These results included an adjusted Earnings Before Interest and Taxes (EBIT) margin of 28.7% and an adjusted Earnings Per Share (EPS) of $1.17, surpassing both consensus and Raymond James’ estimates.

On the other hand, Fortive’s revenue for the fourth quarter was slightly below expectations, coming in at $1.62 billion, compared to the anticipated $1.63 billion. Furthermore, the company’s guidance for 2025, forecasting revenue of $6.23-$6.35 billion, fell short of Wall Street’s projection of $6.47 billion. These developments led to a decrease in Fortive’s stock value.

Despite the mixed financial performance, Fortive announced its plan to separate its Precision Technologies business, which is expected to simplify its complex business structure. This move, according to Raymond James, is a potential value creation catalyst. However, it is important to note that the current geopolitical climate and tariff volatility are affecting Fortive’s business in China, resulting in a guidance that falls below market expectations.

These are recent developments that investors should consider when examining Fortive’s financial health and future prospects. As always, it is crucial to rely on factual information and independent analyses, such as those provided by Raymond James, when making investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.